icon-folder.gif   Conference Reports for NATAP  
 
 

AASLD

The Liver Meeting
Washington DC
October 2017
Back grey_arrow_rt.gif
 
 
 
Real-World Cost-Effectiveness of Elbasvir/Grazoprevir (EBR/GZR) in Treatment-Na´ve (TN) Patients With Chronic Hepatitis C (CHC) Virus Genotype 1 (GT1) in the United States (US)
 
 
  Reported by Jules Levin
AASLD: The Liver Meeting 2017; Washington, DC, USA; October 20-24, 2017
 
Shelby L. Corman1; Bruce Bacon2; Michael P. Curry3; Douglas T. Dieterich4; Steven L. Flamm5; Yiling Jiang6; Kris V. Kowdley7; Scott Milligan8; Chizoba Nwankwo9; Naoky C. Tsai10; Zobair M. Younossi11; Nezam H. Afdhal3 1Pharmerit International, Bethesda, MD, USA; 2Saint Louis University School of Medicine, St. Louis, MO, USA; 3Beth Israel Deaconess Medical Center, Boston, MA, USA; 4Icahn School of Medicine at Mount Sinai, New York, NY, USA; 5Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 6Merck Sharp & Dohme Ltd., Hoddesdon, Hertfordshire, UK; 7Liver Care Network, Swedish Medical Center, Seattle, WA, USA; 8Trio Health Analytics, La Jolla, CA, USA; 9Merck & Co., Inc., Kenilworth, NJ, USA; 10Queens Medical Center, University of Hawaii, Honolulu, HI, USA; 11Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA.

1023171

1023172

1023173

1023174

1023175